NASDAQ:CTSO Cytosorbents Q3 2024 Earnings Results & Report $3.06 -0.03 (-0.97%) Closing price 03:50 PM EasternExtended Trading$3.15 +0.09 (+2.91%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cytosorbents reported Q3 2024 earnings on January 3, 2025. The company reported EPS of -$1.60, while revenue was $8.61 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateJanuary 3, 2025TimeAfter Market Closes Cytosorbents EPS ResultsActual EPS-$1.60Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCytosorbents Revenue ResultsActual Revenue$8.61 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCytosorbents' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesEarnings HistoryCompany Profile Cytosorbents Q3 2024 Earnings FAQ Did Cytosorbents beat earnings estimates for Q3 2024? Cytosorbents (NASDAQ:CTSO) reported earnings of -$1.60 per share for Q3 2024. The report was announced on Friday, January 3, 2025. What was Cytosorbents' revenue for Q3 2024? Cytosorbents reported revenue of $8.61 million for Q3 2024. When is Cytosorbents' next earnings date? Cytosorbents' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cytosorbents on the company's earnings history page. Cytosorbents Earnings HeadlinesAnalyzing Cytosorbents (NASDAQ:CTSO) and Electromed (NYSE:ELMD)October 11, 2026 | americanbankingnews.comContrasting Trinity Biotech (NASDAQ:TRIB) & Cytosorbents (NASDAQ:CTSO)October 11, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 15 at 1:00 AM | Altimetry (Ad)CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical CareSeptember 30, 2026 | prnewswire.comCytosorbents CorpSeptember 25, 2026 | money.usnews.comCytoSorbents Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 23, 2026 | prnewswire.comSee More Cytosorbents Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email. Email Address About CytosorbentsCytosorbents (NASDAQ:CTSO) is a medical device company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent technology to reduce circulating cytokines, inflammatory mediators, toxins and other substances associated with serious illness. The company’s principal product, CytoSorb, is an extracorporeal blood purification device used in critical care and other clinical settings. It is designed to help manage excessive inflammation and is used with existing blood-pumping systems. CytoSorbents has also developed additional products and investigational therapies for applications including cardiac surgery, kidney disease, liver failure and other conditions in which blood purification may be beneficial. Founded in 2001 and headquartered in Princeton, New Jersey, CytoSorbents serves healthcare markets internationally through direct sales and distribution partners. Its products have received regulatory clearances or approvals in various jurisdictions, including Europe, while other products and applications remain under clinical or regulatory review in certain markets.View Cytosorbents ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
